J

Johnson & Johnson

Makes prescription drugs and medical devices

Pharmareferent - Hämatologie

Full-TimeDeadline 11/9/26
€72.8k - €116.7k+ Annual target bonus + Sales commission
Mid
Bachelor's
Neuss, Germany+1 moreMore locations: Munich, Germany
In PersonField-based role covering the Bayern (Bavaria) territory; travel required.
Sales & Account ManagementField Sales

About the job

Requirements
  • A completed degree or doctorate in a natural science, pharmacy, or medicine, or another academic degree.
  • Recognition under § 75(3) as a pharmaceutical sales representative.
  • Confident use of modern IT systems, especially MS Office, databases, iConnect, Veeva, Workday, and digital support, analysis, and training systems.
  • Very good spoken and written German and English.
  • Willingness to travel and a Category B driver’s license.
  • Energy, initiative, an entrepreneurial mindset, and the ability to identify opportunities, set priorities, and remain solution-oriented after setbacks.
  • Curiosity and data orientation, including questioning assumptions and using data and customer-conversation insights to make informed decisions and evaluate the impact of actions.
  • Empathy and customer understanding, including attentive listening and developing approaches that address customer needs.
  • Very good communication and rhetorical skills, negotiation skills, and the ability to present positions clearly and respectfully and follow through on agreements.
  • Ability to work cross-functionally, connect people, understand complex organizational dynamics, and positively influence others.
  • Accountability and execution, including structured organization, ownership from preparation through follow-up, flexibility, and pragmatism.
  • Willingness to learn, digital affinity, ability to quickly understand complex subjects, active use of feedback, and a commitment to continuous development.
Responsibilities
  • Advise customers on the value and benefits of products across analog and digital communication channels and contribute to sales targets.
  • Individually plan and shape customer interactions across all touchpoints using digital planning tools.
  • Build sustainable customer relationships, identify and promote relevant networks, and support market access, collaborations, and patient flow.
  • Monitor the market, competitors, regional developments, and health-policy developments; derive strategies and arguments; and share relevant insights with the cross-functional team.
  • Develop market-access and sales-promotion measures in a competitive environment while using resources appropriately and efficiently.
  • Conduct information events, potentially including presentations, and participate in relevant regional and national training events, meetings, and congresses.
  • Work closely across field-sales lines in the regional cross-functional team, contribute ideas, share knowledge, and support a shared culture of goals, values, and initiative.
Desired Qualifications
  • Business behavior.
  • Clinical experience.
  • Coaching.
  • Competitive landscape analysis.
  • Cross-functional collaboration.
  • Cultural competence.
  • Customer centricity.
  • Data savvy.
  • Developing partnerships.
  • Hematology.
  • Market knowledge.
  • Oncology.
  • Pharmaceutical industry.
  • Pharmaceutical sales marketing.
  • Problem solving.
  • Product knowledge.
  • Sales.
  • Sales enablement.
  • Sales trend analysis.
  • Strategic sales planning.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, NJ

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
The Irish Times
Oct 28th, 2026
Johnson & Johnson buys Irish stroke care firm in multimillion euro deal

Sale of Neuravi is largest deal for a venture-backed medtech in Europe since 2009

Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.